Awm Investment Company, Inc. Oncocyte Corp Transaction History

Awm Investment Company, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.44 - $3.07 $836,649 - $1.05 Million	342,889 Added 45.46%	1,097,175 $3.24 Million
Q4 2023 Feb 14, 2024	BUY	$2.08 - $4.26 $72,808 - $149,117	35,004 Added 4.87%	754,286 $1.89 Million
Q3 2023 Nov 14, 2023	SELL	$0.2 - $4.28 $2.69 Million - $57.6 Million	-13,466,382 Reduced 94.93%	719,282 $2.24 Million
Q2 2023 Aug 11, 2023	BUY	$0.2 - $0.35 $1.48 Million - $2.59 Million	7,412,613 Added 109.44%	14,185,664 $3.26 Million
Q1 2023 May 12, 2023	SELL	$0.2 - $0.49 $96,234 - $235,773	-481,171 Reduced 6.63%	6,773,051 $2.37 Million
Q4 2022 Feb 14, 2023	SELL	$0.25 - $15.6 $123,083 - $7.68 Million	-492,335 Reduced 6.36%	7,254,222 $2.32 Million
Q2 2022 Aug 12, 2022	BUY	$0.86 - $1.53 $6.45 Million - $11.5 Million	7,504,690 Added 3102.82%	7,746,557 $6.97 Million
Q4 2021 Feb 14, 2022	SELL	$2.04 - $3.59 $969,271 - $1.71 Million	-475,133 Reduced 66.27%	241,867 $525,000
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $176,500 - $294,500	50,000 Added 7.5%	717,000 $2.55 Million
Q2 2021 Aug 13, 2021	SELL	$3.77 - $6.0 $312,910 - $498,000	-83,000 Reduced 11.07%	667,000 $3.83 Million
Q1 2021 May 13, 2021	BUY	$2.39 - $6.5 $1.79 Million - $4.88 Million	750,000 New	750,000 $3.89 Million

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $260M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Awm Investment Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Awm Investment Company, Inc. with notifications on news.